TY - JOUR
T1 - The future of antibodies as cancer drugs
AU - Reichert, Janice M.
AU - Dhimolea, Eugen
N1 - Funding Information:
Tuft University's Center for the Study of Drug Development (CSDD) is funded by unrestricted and contract grants from commercial sponsors. This study was funded through CSDD's unrestricted grants and a contract grant from Bayer Healthcare . Dr Reichert has received honoraria from Bayer Healthcare, Merck & Co. and Merrimack Pharmaceuticals.
PY - 2012/9
Y1 - 2012/9
N2 - Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as cancer drugs. To profile products that could be marketed in the future, we examined the current commercial clinical pipeline of mAb candidates for cancer. Our analysis revealed trends toward development of a variety of noncanonical mAbs, including antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies and antibody fragments and/or domains. We found substantial diversity in the antibody sequence source, isotype, carbohydrate residues, targets and mechanisms of action (MOA). Although well-validated targets, such as epidermal growth factor receptor (EGFR) and CD20, continue to provide opportunities for companies, we found notable trends toward targeting less-well-validated antigens and exploration of innovative MOA such as the generation of anticancer immune responses or recruitment of cytotoxic T cells.
AB - Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as cancer drugs. To profile products that could be marketed in the future, we examined the current commercial clinical pipeline of mAb candidates for cancer. Our analysis revealed trends toward development of a variety of noncanonical mAbs, including antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies and antibody fragments and/or domains. We found substantial diversity in the antibody sequence source, isotype, carbohydrate residues, targets and mechanisms of action (MOA). Although well-validated targets, such as epidermal growth factor receptor (EGFR) and CD20, continue to provide opportunities for companies, we found notable trends toward targeting less-well-validated antigens and exploration of innovative MOA such as the generation of anticancer immune responses or recruitment of cytotoxic T cells.
UR - http://www.scopus.com/inward/record.url?scp=84865455090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865455090&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2012.04.006
DO - 10.1016/j.drudis.2012.04.006
M3 - Review article
C2 - 22561895
AN - SCOPUS:84865455090
SN - 1359-6446
VL - 17
SP - 954
EP - 963
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 17-18
ER -
